
BE Therapeutics - Brain Tissue Replacement




Stage
Early stage preclinical discovery
Area
Tissue replacement
Status
Ongoing
Patent Status
Not filed yet
Background
The brain is plastic, and can seamlessly change neural substrates without interrupting functions, and studies have shown that transplanted neurons can integrate into existing adult brain circuits, making it necessary to develop replacement technology for repairing loss of functional brain tissue. The company's product concept involves engineering human brain tissue through reassembling precursor cell types to achieve normal function. The Hébert lab has demonstrated the feasibility of using the adult mouse neocortex to rebuild layered vascularized neocortical tissue in situ, and the engineered tissue can be used to model brain diseases, perform drug screening, and treat localized or diffuse tissue loss caused by trauma, stroke, aging or neurodegeneration. Afflicted areas are cleared of tissue or scar tissue prior to tissue rebuilding, and for diffuse loss of tissue integrity, tissue areas are sequentially rebuilt over time to allow memory and function to relocate.
Aims, Hypothesis & Results
The company aims to develop technology that can engineer functional brain tissue to replace the tissue impaired by age-related damage. They also aim to commercialize this tissue and the methodology for pre-clinical and clinical applications. The initial focus is on repairing damage to the neocortex, followed by other brain areas.
The company hypothesizes that it is possible to engineer functional brain tissue that can replace the tissue that is impaired by age-related damage. They also believe that this technology can be commercialized and applied to treat age-related brain diseases and aging itself.
BE Therapeutics is in the early stages of development, however, they have demonstrated proof of concept in preclinical studies, and their initial focus on repairing damage to the neocortex shows promise for the potential application of this technology to treat age-related brain diseases and aging itself.
Timeline
- Year 1-2: Human Prototype Development
- Identification of cell types and ECM components
- Cell type generation/ ECM production
- Graft assembly - MVP
- Year 3-4:In vivo prototype efficacy studies
- Year 5+: Engage with FDA for clinical trials
Required Funding: $2.2 Mill year 1-2, $3.6 Mill by year 4
Status: Ongoing
Duration: 9+years
VitaDAO Board Evaluation Writeup
The project is categorized as high-risk/high-reward, with high risk being well recognized. The project has many strengths, such as robust experimental data, breakthrough opportunities to address a variety of diseases, a strong scientific approach, a strong founding team, and a reasonable timeline. However, the project also has several risks, including challenges with procuring and using fetal tissue, being a high-risk and long-term project that requires continued funding, and differing responses between mouse and primate models. Feedback from reviewers suggests that careful consideration is needed for some aspects of the project, such as the use of lenti- or retroviruses, regulatory interactions, immunosuppression regimen, surgical procedures and devices for application, and cGMP-compliant manufacturing.

Non Consectetur Necessitatibus
Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

Eum Harum Asperiores Id
Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

Ex Temporibus Perferendis
Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

Dolorum Quia
Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

Earum Est Dolorem
Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

Culpa Possimus
Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

Aperiam Et Quis Et
Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

Voluptas Quam Sapiente
Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

Aut Accusantium Ut
Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

Nisi
Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l
Discover more projects & initiatives

Humanity
Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

Matrix Bio
VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.

ExcepGen Inc - RNA therapeutics for longevity
ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.

Discovering Novel Autophagy Activators
Autophagy - the mechanism to recycle cellular components - becomes dysregulated with age and is associated with numerous diseases. The Korolchuk lab, based at Newcastle University, will screen a compound library to identify novel autophagy-activating compounds with the aim of restoring autophagy function to aged cells.